Consequently, in patients with MVA with endothelial dysfunction the administration of PDE-5 inhibitors may significantly restore the NO-dependent vasodilation, leading to symptom improvement and improved perfusion in CMR. The gene discussed is PDE5A; the disease is endothelial dysfunction.